NCT04770831Withdrawn
Patients Who Receive 131 I-MIBG
An Observational Study of Patients With Recurrent Progressive or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Who Receive 131 I- MIBG
Source: ClinicalTrials.gov · Last updated 14 Dec 2022
Reason given: difficult enrollment, no subjects consented or enrolled
Brief summary (registry, in English)
This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.
- Status (registry)
- Withdrawn
- Study type
- Observational
- Enrollment
- 0 (actual)
- First submitted
- 16 Feb 2021
- Start date
- 10 Mar 2021
- Primary completion date
- Dec 2024
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Neuroblastoma
- NCT number
- NCT04770831
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior enrollment on LCI-PED-NEU-MIBG-001 trial.
Other
- Subjects meeting the criteria below may not participate in the study:
Who the study is looking for
- Subject must meet all of the following applicable inclusion criteria to participate in this study:
- Written informed consent, and assent where applicable, and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- Age greater than or equal to 1 years and less than or equal to 30 years at the time of therapy.
- Subject is scheduled to receive 131 I-MIBG therapy.
- Diagnosis of refractory, progressive or relapsed Neuroblastoma, Malignant Paraganglioma, Malignant Pheochromocytoma or other Neuroendocrine Tumors.
- As determined by the enrolling physician, ability of the subject and parent/caregiver to understand and comply with study procedures for the entire length of the study.
Age in the registry: 1 year to 30 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Cancer Institute | Charlotte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.